Proteins in blood could provide early cancer warning 'by more than seven years'
Researchers have identified blood proteins that may signal certain cancers more than seven years before diagnosis, prompting hope for earlier and more effective intervention. Commenters compare this approach to existing blood tests like GRAIL’s cfDNA-based Galleri, explore how protein markers might complement other screening tools, and question how reliably they can pinpoint cancer type or severity. Many are optimistic about lives saved through early detection, but others warn about overdiagnosis, anxiety, unnecessary treatment, and the ethical and insurance implications of widespread screening.
Overall Reaction & Promise
- Many commenters are excited; a 7‑year lead time is seen as a “huge win” if it works in practice.
- The approach feels clearer and more testable than many cancer headlines; people hope it can be replicated or disproven quickly.
- Some imagine pairing very‑early detection with mRNA or other targeted treatments within the next decade.
Comparison to Existing Tests & Biomarkers
- This study focuses on protein biomarkers; existing commercial products (e.g., Galleri) mainly use cfDNA and DNA methylation patterns.
- Proteins are seen as a complementary signal that might boost sensitivity and specificity when combined with cfDNA.
- Longstanding markers like CA 19‑9 for pancreatic cancer are mentioned; posters note we’ve been hunting blood biomarkers for decades.
Cancer Types & Current Limits
- The cited paper reportedly found little evidence for pancreatic, thyroid, lip/oral, or melanoma cancers after multiple‑testing correction.
- Some mention Galleri’s claim to be relatively good at detecting aggressive cancers like pancreatic via cfDNA.
- Concerns arise about distinguishing lethal cancers from indolent ones that might never affect lifespan.
Screening Benefits vs Harms
- Repeated discussion of overdiagnosis: more detected cancers but unchanged mortality (e.g., thyroid, some skin and prostate cancers).
- False positives drive anxiety, invasive follow‑ups, and sometimes harmful treatment without survival benefit.
- Several refer to national systems (Netherlands, UK) that deliberately limit testing based on population‑level cost‑effectiveness and QALY‑style thresholds.
- Examples: mammography radiation risk; prostate cancer often managed conservatively, especially in older men; skepticism of full‑body MRI screening.
Actionability, Anxiety & Individual Stories
- Key questions: what can you do with a 7‑year warning, and is there treatment that early?
- Some argue lifestyle changes and earlier, targeted follow‑up imaging could be valuable; others fear years of nocebo, stress, and depression.
- Anecdotes: a blood donor flagged for elevated immunoglobulins is undergoing slow, cautious follow‑up; others describe scares from routine labs that ultimately meant nothing.
Insurance, Ethics & System Design
- US commenters worry about mandatory testing and insurer misuse, though others note current ACA rules limit health‑insurance discrimination while life/long‑term‑care remain exposed.
- Debate over whether cost‑driven test aversion in public systems reflects justified evidence‑based policy or simple rationing.
Data, Models & Future Outlook
- Some want broad, frequent testing to build longitudinal datasets and refine models; others stress that more data isn’t always good when medicine is noisy and incentives skewed.
- Consensus: this is an intriguing early step that must be proven to improve real‑world outcomes, not just earlier detection.